Anxicam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anxicam

What is Anxicam?

Anxicam is a pharmacological treatment belonging to the benzodiazepine class of medications. It is primarily utilized for its therapeutic effects on the central nervous system to manage symptoms associated with various forms of anxiety and related conditions.

Mechanism of Action

The active component in Anxicam works by enhancing the activity of gamma-aminobutyric acid (GABA), which is the primary inhibitory neurotransmitter in the brain. By facilitating the binding of GABA to its receptors, the medication helps to reduce the over-excitation of neurons. This process results in a calming effect on the nervous system, which can help alleviate the physiological and psychological manifestations of acute distress.

Therapeutic Properties

Anxicam possesses several distinct pharmacological properties that contribute to its clinical utility:

  • Anxiolytic: Reduces feelings of intense anxiety, apprehension, and nervous tension.
  • Sedative: Promotes a state of relaxation and calmness.
  • Anticonvulsant: Helps in stabilizing electrical activity in the brain.
  • Muscle Relaxant: Assists in reducing physical tension in the skeletal muscles.

Clinical Indications

This medication is typically indicated for the short-term management of severe or disabling anxiety. It may be used to address generalized anxiety symptoms or anxiety associated with transient stressful events. In some clinical settings, it is also employed as a premedication to assist with relaxation before medical or dental procedures, or as an adjunctive treatment for certain types of sleep disturbances when anxiety is a primary contributing factor.

Regulatory References

  1. Lorazepam Drug Information (DailyMed/NIH)
  2. CNS Depressants (NIDA/NIH)
  3. NIH Bookshelf
  4. Lorazepam Product Info (NIH Bookshelf)
  5. Lorazepam Indications (NIH Bookshelf)
  6. Lorazepam Half-life and Pharmacokinetics (NIH)
  7. Lorazepam Dosage Forms (DailyMed/NIH)
  8. Lorazepam Oral Solution Label (DailyMed/NIH)
  9. Lorazepam Mechanism of Action (NIH/ClinPGx)
  10. Lorazepam Macure SmPC (HPRA/European Register)
  11. Lorazepam Preoperative Use (NIH Bookshelf)

What side effects are possible with Anxicam?

Possible Side Effects and Safety Information

The safety profile of Anxicam (Lorazepam) is defined by categories of adverse reactions documented in regulatory documents, with a high incidence of effects related to Central Nervous System (CNS) depression.

Documented Adverse Reactions and Frequency

Adverse reactions are classified by frequency based on official prescribing information:

Frequency Classification Examples of Documented Effects
Very Common Sedation, Drowsiness (Somnolence)
Common Ataxia (impaired coordination), Dizziness, Fatigue, Muscle Weakness
Uncommon Nausea

Effects like dependence, withdrawal symptoms, and paradoxical reactions (such as agitation or hostility) are also documented, with their frequency generally classified as not known from available data.

Systemic Safety Patterns

The most frequently reported side effects are grouped under Nervous System Disorders and Psychiatric Disorders, including confusion, amnesia, and emotional blunting. These CNS effects are most frequently observed at the start of treatment and commonly diminish with continued use. Conversely, long-term exposure carries a well-documented risk of developing physical and psychological dependence, with the potential for rebound anxiety or intensified symptoms upon cessation.

Serious Adverse Reactions and Restrictions

Serious adverse reactions noted in official labeling include the risk of Respiratory Depression, especially with rapid administration, and severe, though rare, hypersensitivity reactions such as anaphylaxis. The safety profile also identifies specific populations and conditions requiring caution or restriction.

Safety Consideration Regulatory Note
Older Adults Increased sensitivity and greater risk of sedation, dizziness, and ataxia.
Contraindications Use is restricted in patients with severe hepatic impairment, acute narrow-angle glaucoma, and severe respiratory insufficiency.

These official safety statements structure the understanding of the medicine's risk, focusing on managing initial CNS effects and the constraints related to duration of use and patient comorbidities.

Overdose and Emergency Response

The official regulatory documents define Anxicam (Lorazepam) overdose as an extreme expression of its CNS depressant properties. Documented manifestations range from common signs such as somnolence and confusion to physical indicators like ataxia (unsteadiness) and dysarthria (slurred speech).


Severe Outcomes and Emergency Action

The most severe, life-threatening outcomes are respiratory depression and profound sedation, which can progress to coma and, potentially, death. Regulatory information emphasizes that this risk is heightened significantly if the substance is co-ingested with other CNS depressants, such as alcohol or opioids. Official guidance mandates that any suspected overdose requires the user to seek immediate medical attention. Users must contact emergency services immediately if severe symptoms like respiratory compromise are present.


Supportive Management

The standard regulatory approach defines treatment as primarily symptomatic and supportive care, necessitating close observation in a hospital setting until clinical stability is achieved. Supportive measures may include airway management for severe respiratory depression and continuous monitoring of vital signs. The antagonist Flumazenil is available; however, regulatory documents contain a specific caution against its routine use due to the documented risk of precipitating seizure activity. Elderly and debilitated patients are noted to be more susceptible to the severe sedative effects.

Therapeutic Uses of Anxicam

What Anxicam Treats: Main Uses and Benefits

Anxicam (Lorazepam) is commonly used to manage conditions characterized by periods of heightened symptoms related to severe anxiety and panic. It is applied in situations involving certain distressing symptoms, including intense agitation, restlessness, and acute physical tension. This use generally assists with supporting functional stability and offers symptomatic relief that helps patients cope more steadily with difficult episodes.

The medication is relevant in acute medical settings for its ability to promptly address symptoms of increased neurological activity. Its primary therapeutic domains include areas such as managing anxiety disorders, providing pre-procedural sedation, addressing symptoms of continuous seizure activity (Status Epilepticus), and supporting patients during acute alcohol withdrawal syndrome. Its intended use is to support the patient during difficult episodes by contributing to easing the overall symptom load of neurological hyperactivity.

“Its intended use is to support the patient during difficult episodes by contributing to easing the overall symptom load of neurological hyperactivity.”


Quick Fact: Relief for Severe Acute Symptoms

Symptom Domain General Benefit
Severe Anxiety/Panic Assists with maintaining functional stability and composure.
Continuous Seizure Activity Relevant for the prompt management of neurological instability.
Acute Withdrawal Supports the patient by easing the burden of systemic imbalance.

Eligibility and Restrictions for Use

Anxicam (Lorazepam) eligibility is strictly defined by regulatory bodies based on age, existing health conditions, and physiological states. Use is generally established for adults under standard labeled conditions, but several absolute exclusions and restrictions apply.

Who Is Strictly Contraindicated

Individuals must not use Anxicam if they have a known hypersensitivity to benzodiazepines or to any component of the formulation. The medicine is also strictly contraindicated for patients diagnosed with acute narrow-angle glaucoma.

Restrictions and Conditional Use

Eligibility is restricted for certain age groups, as safety and efficacy are not established for children under 12 years of age. Elderly or debilitated patients must receive a lower initial dosage and require closer monitoring. The label mandates caution in patients with severe hepatic insufficiency or compromised respiratory function. Furthermore, use is not recommended for patients whose primary condition is a depressive disorder or psychosis.

Pregnancy and Lactation Status

Use should be avoided during the late phase of pregnancy and at delivery due to risks to the newborn. Anxicam is generally not recommended for women who are breastfeeding unless the potential clinical benefit to the mother outweighs the risk to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Anxicam across several domains, primarily focusing on pharmacodynamic and pharmacokinetic effects with concomitant use of other products.

Pharmacodynamic (PD) Interactions

Co-administration with other Central Nervous System (CNS) depressants, including alcohol, opioid analgesics, and other sedative medications (such as certain antipsychotics, anxiolytics, and antihistamines), results in additive CNS depressant effects. Regulatory guidance states that co-prescribing with opioids must be strictly limited to cases where no alternative treatment options are adequate, and requires using the lowest effective dosages for the minimum duration.

Pharmacokinetic (PK) Interactions

Interactions involving changes to Anxicam's metabolism are a major concern. Anxicam is cleared primarily through metabolic pathways involving specific enzymes.

  • Contraindicated Combinations: Concomitant use with strong inhibitors of the CYP3A enzyme, such as ketoconazole and itraconazole, is officially contraindicated. This is because these agents significantly decrease the clearance of Anxicam, leading to potentially increased plasma concentrations and risk of adverse effects.
  • Caution and Monitoring: Agents that induce the CYP3A enzyme may increase Anxicam's clearance, potentially reducing its clinical effectiveness. Furthermore, Anxicam may increase the serum concentrations of co-administered drugs like digoxin, which necessitates monitoring to prevent toxicity.

Patients should be advised against operating heavy machinery or driving when combining Anxicam with any other substance that produces CNS depression.

Mechanism of Action

Anxicam, a benzodiazepine, acts as a positive allosteric modulator primarily targeting the gamma-aminobutyric acid type A (GABAA) receptor complex within the central nervous system.

The GABAA receptor is a ligand-gated chloride-selective ion channel. Anxicam binds to a distinct allosteric site located at the interface of the receptor's alpha and gamma subunits. This binding does not directly activate the channel, but rather increases the affinity of the primary inhibitory neurotransmitter, GABA, for its own binding sites.

The molecular consequence is an enhanced frequency of chloride ion channel opening when GABA is present. This results in an increased influx of negatively charged chloride ions (Cl^-) into the postsynaptic neuron. This increased negative intracellular charge leads to neuronal membrane hyperpolarization. The hyperpolarized state raises the necessary threshold for action potential generation, effectively reducing neuronal excitability and the overall rate of nerve signal transmission across multiple brain regions, including the limbic system and cortex. This systemic modulation corresponds to a state of reduced nervous system arousal.

Dosage and Administration Information

Official Administration Guidelines

Anxicam (Lorazepam) is administered via both oral and parenteral routes, including intravenous (IV) and intramuscular (IM) injection. The specific use pattern is determined by the condition being addressed, with the oral form typically utilized for routine use and the injection reserved for acute medical settings, where it requires specialist supervision.

Dosing and Frequency

The total daily dose of the oral form is generally between 2 mg and 6 mg for anxiety, typically taken in divided doses two or three times per day. For the labeled use in insomnia, the medicine is administered as a single dose of 2 mg to 4 mg immediately before bedtime. The maximum total daily dose for the oral form is 10 mg. In the geriatric population or for patients with hepatic impairment, the initial dose is generally lower, often halved, and then adjusted based on the patient’s response.

Administration Conditions and Duration

Oral forms may be taken with or without food. Liquid concentrates must be diluted with a beverage or soft food immediately prior to consumption. The IV solution must also be diluted with a compatible diluent before administration. Official documentation specifies that Anxicam is intended for short-term use, generally 2 to 4 weeks. Discontinuation of the medicine requires a gradual dosage tapering to reduce the potential for withdrawal reactions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anxicam

Evidence for use in Severe Anxiety Disorders

Anxicam was studied for conditions characterized by severe anxiety disorders in adults. The studies conducted were primarily controlled trials, which means Anxicam was compared against a placebo or another research scenario to see how symptoms evolved in the observed populations over a defined time interval. Findings indicate that in the populations studied, research highlights changes measured during the study period. However, results apply only to the studied populations, and follow-up durations were limited, meaning the full extent of symptom patterns beyond the short term is not fully established.


Evidence for use in Muscle Spasms

Research examined Anxicam in studies involving conditions marked by functional limitations, such as those related to skeletal muscle spasms. Studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning. Data show patterns related to outcomes reflecting daily functioning when Anxicam was observed alongside other approaches. However, sample sizes were modest, and the duration of observation was short. Evidence quality varies across studies.


Long-term Studies and Follow-up

Most research conducted on Anxicam has involved limited follow-up durations. Research highlights changes measured during these shorter study periods, but there is limited information for long-term outcomes, particularly extending beyond a few months. Studies that have followed patients over extended periods were associated with varying symptom burdens, and those findings were mixed regarding how well the initial changes were maintained. Therefore, long-term effects are not fully established.


What is Still Uncertain About Anxicam

Despite the research conducted, several areas remain uncertain. Comparative evidence is lacking against many other established therapies. Findings were mixed in some trials, particularly regarding the long-term maintenance of observed changes. While studies help show what has been observed so far, the research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Anxicam (FAQ)


Q: What is the information regarding consuming alcohol while taking Anxicam?

Regulatory documents contain warnings that consuming alcohol while using Anxicam can increase the risk of serious problems. This is because both substances act as central nervous system (CNS) depressants, which can lead to excessive sleepiness, severe dizziness, and trouble breathing.


Q: Is Anxicam generally considered suitable for older adult patients?

Official guidelines recommend caution when prescribing Anxicam to older adults. Because this population may be more sensitive to the medicine's effects, official guidance often suggests a lower initial dose. This practice is employed to help reduce the risk of effects like increased drowsiness or dizziness.


Q: What pre-existing medical conditions might make Anxicam unsuitable for a person?

Regulatory documents list certain conditions that may influence the decision to use Anxicam, including acute narrow-angle glaucoma, severe respiratory insufficiency, severe liver disease, and myasthenia gravis. A history of substance abuse is also noted in regulatory documents as requiring careful surveillance.


Q: Are there any long-term health concerns associated with taking Anxicam for several years?

Official regulatory information states Anxicam is generally intended for short-term use. Longer use is associated with an increased risk of developing physical and psychological dependence. Regulatory bodies highlight the need for periodic re-evaluation for long-term use.


Q: What are the known drug-condition interactions for Anxicam?

Official documents caution about the use of Anxicam in patients with certain pre-existing health issues. This includes individuals with compromised respiratory function (e.g., sleep apnea or COPD) and those with severe hepatic (liver) insufficiency, due to the potential for adverse effects in these groups.


Q: How long does it usually take to feel the first effects of Anxicam?

According to official product information on pharmacokinetics (how the body handles the drug), when Anxicam is taken orally, the initial effects are generally reported to begin within 20 to 30 minutes after consumption.


Q: What are the most common reported side effects of Anxicam?

The most frequently reported side effects listed in official regulatory documents are feelings of drowsiness, dizziness, weakness, and unsteadiness. These effects are listed as common.


Q: What are the known serious side effects of Anxicam?

Serious reported effects include slowed or difficult breathing, yellowing of the skin or eyes (jaundice), signs of a severe allergic reaction (such as swelling of the face or throat), and the potential for suicidal thoughts or actions.


Q: Is fatigue or drowsiness a frequently reported side effect of Anxicam?

Yes, regulatory documents list both drowsiness and fatigue as commonly reported adverse reactions associated with Anxicam.


Q: Is insomnia (difficulty sleeping) a known side effect when taking Anxicam?

Insomnia, or difficulty sleeping, is listed in official documents as a potential side effect. It is also noted that insomnia may occur as a 'rebound' symptom after the medicine is stopped.


Q: Does Anxicam interact with any specific foods or supplements?

Official regulatory information does not typically list specific foods or common non-herbal beverages as having significant interactions with the medicine. However, specific dietary considerations are part of the full prescribing information.


Q: What happens if a person misses a single dose of Anxicam?

Official patient information describes scenarios for a missed dose, typically noting that if the next scheduled dose is approaching, the missed dose is skipped. These instructions are provided in the full prescribing information.


Q: How long does the effect of a single dose of Anxicam typically last?

Regulatory documents on the medicine's properties indicate that the duration of clinical effect following a single oral dose is typically reported to be about six to eight hours.


Q: Is there information about Anxicam's effect on sex drive or performance?

Official documents list changes in libido (sex drive) as a possible, though less frequent, adverse reaction associated with the use of Anxicam.


Q: Does Anxicam affect blood pressure or heart rate?

Official documents list low blood pressure (hypotension) and changes in heart rate, such as a fast or slow heartbeat, as potential, though less common, serious side effects that have been reported.


Q: What are the risks associated with taking Anxicam during pregnancy or breastfeeding?

Official documents advise against use during pregnancy, particularly in the later stages, due to the risk of the drug potentially causing neonatal sedation or withdrawal syndrome. Official documents state that breastfeeding is generally advised against during use, as the medicine is excreted into human milk.


Q: What are the symptoms of a potential drug-drug interaction involving Anxicam?

Official warnings state that combining Anxicam with other central nervous system (CNS) depressants can result in severe interaction symptoms. These can include profound sedation, extreme sleepiness, respiratory depression, and potentially coma.


Q: Do studies suggest Anxicam is associated with any specific mood changes like increased agitation?

Regulatory documents note that paradoxical reactions, which are responses opposite to the intended effect, have been reported in some patients. These have included mood changes such as increased agitation, aggression, or hostility.


Q: Is it normal to have vivid dreams or changes in sleep patterns when taking Anxicam?

Official documents on adverse reactions note that changes in sleep patterns, which may include nightmares, are listed as potential side effects.


Q: What information is available about Anxicam and mental focus or concentration?

Official documents list difficulty concentrating or memory problems as potential side effects. These effects are often tied to the medicine's known action as a central nervous system depressant.


Q: Are there known interactions between Anxicam and recreational substances (informational only)?

Official documents contain strong warnings against combining Anxicam with other central nervous system depressants, including alcohol. Misuse of the drug in combination with other substances carries a risk of serious, life-threatening side effects, such as profound respiratory depression.


Q: Is Anxicam safe to take if a person has a history of substance abuse (descriptive eligibility)?

Regulatory documents indicate that the risk of developing dependence or misuse is increased in patients with a history of alcoholism or drug abuse. Therefore, careful surveillance is warranted for individuals in this population.


Q: Can Anxicam cause headaches or dizziness?

Yes, headaches and dizziness are listed in official documents as commonly reported side effects of Anxicam.


Q: Is Anxicam chemically similar to any other well-known anxiety drugs?

Official regulatory sources classify Anxicam (Lorazepam) as a benzodiazepine. This is a class of medicines that includes other well-known drugs used to address anxiety-related conditions.


Q: Is Anxicam available as a generic version, and is it comparable to the brand name?

Official product information confirms that the active ingredient, Lorazepam, is the generic equivalent of Anxicam. The generic version is available in various forms and, as is typical with generic equivalents, is chemically identical to the brand name’s active ingredient.


Q: Is it common for people to experience temporary side effects when first starting Anxicam?

Official documents list common side effects such as drowsiness and unsteadiness. They also note that some side effects may lessen or go away within a few days or a couple of weeks after a person begins treatment.


Q: Are there different forms of Anxicam available (e.g., tablet, capsule, liquid)?

The medicine is officially available in multiple formulations. These include oral tablets, oral solution (often referred to as a liquid concentrate), and an injectable solution (used primarily in acute medical settings).


Q: Are there any special considerations for people with liver or kidney issues who take Anxicam?

Regulatory documents advise caution for patients with compromised renal (kidney) function. Additionally, they recommend caution and may necessitate a lower initial dosage for individuals with severe hepatic (liver) impairment.


Q: What are the ingredients of the prescribed Anxicam product?

The active ingredient in Anxicam is Lorazepam, a chemical compound. Official sources provide the specific chemical name and structure of the medicine’s active component.


Q: Is Anxicam known to cause or worsen anxiety in the initial stages of treatment?

Anxiety is listed as a potential paradoxical reaction that has been reported in regulatory documents. A paradoxical reaction is a response that is the opposite of the intended therapeutic effect.


Q: Why do some people report feeling worse before they feel better on Anxicam?

Official documents list potential adverse reactions such as increased anxiety, agitation, and hostility. These paradoxical effects may be reported by some patients and could contribute to the feeling of transient worsening of symptoms.


How should Anxicam be stored and disposed of?

How to Store and Dispose of Anxicam? (Lorazepam)

Anxicam (Lorazepam) must be stored under specific environmental and packaging conditions to maintain product integrity and safety, as defined by regulatory documents.

Storage Conditions

Requirement Details
Temperature Store at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection Keep the medicine protected from light and moisture.
Container Store in the original container, which must be tightly closed.
Prohibited The product must not be frozen.
Child Safety It is required to keep this medicine out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Lorazepam must follow official procedures. The medicine should not be flushed down the toilet or poured into a drain. Disposal should be completed by taking the product to an authorized drug take-back location or by consulting a pharmacist for guidance on proper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anxicam found in:

A-Z Index: